Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Fedor Moiseenko's publication output changed over time?
ScholarIQpublication output · 2019–2024
Output grew0% over the shown period — from 1 works in 2019 to 1 in 2024.
1
1
1
201920222024
What are the most-cited papers on Fedor Moiseenko?
ScholarIQmost cited works
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Ying Cheng, Liang Han, Lin Wu, Jun Chen, Hongmei Sun, Guilan Wen, Yinghua Ji, Mikhail Dvorkin, Jianhua Shi, Zhijie Pan, Jinsheng Shi, Xicheng Wang, Yuansong Bai, Tamar Melkadze, Yueyin Pan, Xuhong Min, Maksym Viguro, Xingya Li, Yanqiu Zhao, Junquan Yang, Tamta Makharadze, Ekaterine Arkania, Wenying Kang, Qingyu Wang, Jun Zhu, ASTRUM-005 Study Group, Xiubao Ren, Vladimer Kuchava, Guoping Sun, Gaofeng Li, Lin Wen, Tao Zhang, Hakan Harputluoğlu, İrfan Çiçin, Guosheng Feng, Yanrong Hao, Kejing Ying, Ping Sun, Aihong Zhong, Guangyu An, Yan Wang, Chun Chen, Sheng Yang, Zhendong Chen, Konstantin Penkov, Yuriy Semegen, Oleg Kobziev, Feng Luo, Peiguo Cao, Zhixiong Yang, Min Fan, Wen Li, Robert Mróz, А. Л. Акопов, Tuncay Göksel, Mahmut Gümüş, Wenlei Zhuo, Jian Fang, Hui Zhao, Lin Zhong, Yanping Hu, Yarong Li, Shuqun Zhang, Jiuwei Cui, Н. В. Коваленко, Çağatay Arslan, Devrim Cabuk, Alev Türker, Igor Bondarenko, Yevhen Hotko, O. Goloborodko, Dongji Chen, Mengzhao Wang, Zhuang Yu, Jun‐Guo Lu, Liyan Jiang, Hao Xiong, Davit Giorgadze, Sergey Orlov, Ahmet Bılıcı, Ivan Sinelnikov, Gongyan Chen, Yue Lu, Xiaoli Zhu, Liqin Lu, Mariam Zhvania, Małgorzata Ułańska, Igor Lifirenko, Timur Andabekov, Maria Smagina, Fedor Moiseenko, Yüksel Ürün, Ligong Nie, Bangwei Cao, Zhenyu You, Haixin Huang, Shenpeng Ying, Alexandre Tavartkiladze, Tariel Kitiashvili, Amiran Matitashvili
JAMA. 2022469 CitationsOPEN ACCESS
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Jonathan W. Goldman, Fedor Moiseenko, Е. А. Филиппова, İrfan Çiçin, Tudor–Eliade Ciuleanu, Nathalie Daaboul, Chunling Liu, Penelope A. Bradbury, Mor Moskovitz, Nuran Katgı, Pascale Tomasini, Alona Zer, Nicolas Girard, Kristof Cuppens, Ji‐Youn Han, Shang‐Yin Wu, Shobhit Baijal, Aaron S. Mansfield, Chih‐Hsi S. Kuo, Kazumi Nishino, Se‐Hoon Lee, David Planchard, Christina S. Baik, Martha Li, Peter Ansell, Summer Xia, Ellen Bolotin, Jim Looman, Christine K. Ratajczak, Shun Lü
Journal of Clinical Oncology. 2024158 CitationsOPEN ACCESS
Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC
M. Stepanova, Fedor Moiseenko, A.S. Zhabina, В. В. Клименко, N. Rysev, A.V. Myslik, E.V. Artemieva, Ksenya V. Shelekhova, An.A. Bogdanov, Nikita Volkov, В. Моисеенко
Annals of Oncology. 20191 CitationsOPEN ACCESS
Related on ScholarIQ
Leningrad Regional Cancer Center
Institution
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer
Paper
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial
Paper
Investigation of the mechanisms of resistance to osimertinib in patients with T790M-associated NSCLC
Paper
Lung Cancer Treatments and Mutations
Topic
Colorectal Cancer Treatments and Studies
Topic